{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:02:16Z","timestamp":1720382536545},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.leukres.2018.01.005","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T18:17:18Z","timestamp":1515003438000},"page":"74-79","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations"],"prefix":"10.1016","volume":"65","author":[{"given":"Koiti","family":"Inokuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Yokose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.01.005_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2018.01.005_bib0010","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelogenous leukemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2018.01.005_bib0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0165-4608(99)00187-9","article-title":"FISH study of variant Philadelphia rearrangement","volume":"118","author":"Reddy","year":"2000","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.leukres.2018.01.005_bib0020","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.005_bib0025","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.005_bib0030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.005_bib0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2141.2003.04291.x","article-title":"Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia","volume":"121","author":"Reid","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0040","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.005_bib0045","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0145-2126(92)90045-9","article-title":"Relationship of the type of bcr-abl hybrid mRNA to clinical courses and transforming activity in Philadelphia-positive chronic myelogenous leukemia","volume":"16","author":"Futaki","year":"1992","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2018.01.005_bib0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/(SICI)1098-2264(199811)23:3<227::AID-GCC4>3.0.CO;2-3","article-title":"Establishment of a cell line with variant BCR\/ABL breakpoint expressing P180BCR\/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia","volume":"23","author":"Inokuchi","year":"1998","journal-title":"Genes. Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2018.01.005_bib0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02983390","article-title":"Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia","volume":"78","author":"Inami","year":"2003","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0060","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-013-1483-9","article-title":"Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia","volume":"99","author":"Kumagai","year":"2014","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3960\/jslrt.54.197","volume":"54","author":"Inokuchi","year":"2014","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.leukres.2018.01.005_bib0075","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood.V78.12.3125.3125","article-title":"A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia","volume":"78","author":"Inokuchi","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.005_bib0080","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1532\/IJH97.05186","article-title":"Oral administration of imatinib to P230 BCR\/ABL-expressing transgenic mice changes clones with high BCR\/ABL complementary DNA expression into those with low expression","volume":"84","author":"Inami","year":"2006","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02983390","article-title":"Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia","volume":"78","author":"Inami","year":"2003","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0090","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.01.005_bib0095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00432-016-2321-2","article-title":"No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib","volume":"143","author":"Pfirrmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0100","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.005_bib0105","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","article-title":"Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISON 5-year final report","volume":"105","author":"Nakamae","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0110","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.01.005_bib0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.005_bib0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3960\/jslrt.50.91","article-title":"11q23\/MLL acute leukemia: update of clinical aspects","volume":"50","author":"Tamai","year":"2010","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.leukres.2018.01.005_bib0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.leu.2402766","article-title":"New mechanisms of AML1 gene alteration in hematological malignancies","volume":"17","author":"Roumier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.01.005_bib0130","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2018.01.005_bib0135","doi-asserted-by":"crossref","first-page":"e87637","DOI":"10.1371\/journal.pone.0087637","article-title":"Identification of novel genomic aberrations in AML-M5 in a level of array CGH","volume":"11","author":"Zhang","year":"2014","journal-title":"PLoS One"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T05:21:36Z","timestamp":1603603296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618300055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":27,"alternative-id":["S0145212618300055"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.01.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}